Research progress on PI3K/AKT/mTOR signal pathway in lymphoma
10.3969/j.issn.1000-8179.2016.05.388
- VernacularTitle:PI3K/AKT/mTOR信号通路抑制剂在淋巴瘤中的研究进展
- Author:
Hui LIU
;
Xin LI
;
Tengpeng HU
;
Zhenchang SUN
;
Mingzhi ZHANG
- Publication Type:Journal Article
- Keywords:
lymphoma;
signal transduction;
PI3K/Akt/mTOR signal pathway;
targeted therapy
- From:
Chinese Journal of Clinical Oncology
2016;43(5):211-215
- CountryChina
- Language:Chinese
-
Abstract:
The phosphoinositide-3 kinase (PI3K)/protein kinase B (PKB/AKT)/mammalian target of rapamycin (mTOR) pathway is asso-ciated with cell growth, proliferation, differentiation, apoptosis and metabolism. The abnormalities of this signal pathway are found in various malignant tumors. This pathway has also been investigated as an anti-tumor target. Recently, novel inhibitors have been stud-ied in clinical trials of lymphoma. This review summarizes the activation status of the PI3K/AKT/mTOR pathway and its use for targeted therapy of lymphoma.
